A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048

Abstract:
        Abstract
        
          Background
          MMV390048 is the first Plasmodium phosphatidylinositol 4-kinase inhibitor to reach clinical development as a new antimalarial. We aimed to characterize the safety, pharmacokinetics, and antimalarial activity of a tablet formulation of MMV390048.
        
        
          Methods
          A 2-part, phase 1 trial was conducted in healthy adults. Part 1 was a double-blind, randomized, placebo-controlled, single ascending dose study consisting of 3 cohorts (40, 80, 120 mg MMV390048). Part 2 was an open-label volunteer infection study using the Plasmodium falciparum induced blood-stage malaria model consisting of 2 cohorts (40 mg and 80 mg MMV390048).
        
        
          Results
          Twenty four subjects were enrolled in part 1 (n = 8 per cohort, randomized 3:1 MMV390048:placebo) and 15 subjects were enrolled in part 2 (40 mg [n = 7] and 80 mg [n = 8] cohorts). One subject was withdrawn from part 2 (80 mg cohort) before dosing and was not included in analyses. No serious or severe adverse events were attributed to MMV390048. The rate of parasite clearance was greater in subjects administered 80 mg compared to those administered 40 mg (clearance half-life 5.5 hours [95% confidence interval {CI}, 5.2–6.0 hours] vs 6.4 hours [95% CI, 6.0–6.9 hours]; P = .005). Pharmacokinetic/pharmacodynamic modeling estimated a minimum inhibitory concentration of 83 ng/mL and a minimal parasiticidal concentration that would achieve 90% of the maximum effect of 238 ng/mL, and predicted that a single 120-mg dose would achieve an adequate clinical and parasitological response with 92% certainty.
        
        
          Conclusions
          The safety, pharmacokinetics, and pharmacodynamics of MMV390048 support its further development as a partner drug of a single-dose combination therapy for malaria.
        
        
          Clinical Trials Registration
          NCT02783820 (part 1); NCT02783833 (part 2).

SEEK ID: https://fairdomhub.org/publications/658

DOI: 10.1093/cid/ciaa368

Projects: WP 4: Evaluation of drug activity against multiple life cycle stages of ...

Publication type: Journal

Journal: Clinical Infectious Diseases

Citation: Clinical Infectious Diseases 71(10):e657-e664

Date Published: 15th Nov 2020

Registered Mode: by DOI

Authors: James S McCarthy, Cristina Donini, Stephan Chalon, John Woodford, Louise Marquart, Katharine A Collins, Felix D Rozenberg, David A Fidock, Mohammed H Cherkaoui-Rbati, Nathalie Gobeau, Jörg J Möhrle

help Submitter
Citation
McCarthy, J. S., Donini, C., Chalon, S., Woodford, J., Marquart, L., Collins, K. A., Rozenberg, F. D., Fidock, D. A., Cherkaoui-Rbati, M. H., Gobeau, N., & Möhrle, J. J. (2020). A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048. In Clinical Infectious Diseases (Vol. 71, Issue 10, pp. e657–e664). Oxford University Press (OUP). https://doi.org/10.1093/cid/ciaa368
Activity

Views: 79

Created: 9th Jan 2023 at 10:30

Last updated: 9th Jan 2023 at 10:30

help Tags

This item has not yet been tagged.

help Attributions

None

Powered by
(v.1.13.0)
Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH